

## Synthesis and applications of new *trans* 1-indolyl-2-(1-methylpyridinium and quinolinium-2-yl)ethylenes

Cosimo G. Fortuna,\* Vincenza Barresi, Nicola Musso, and Giuseppe Musumarra

Dipartimento di Scienze Chimiche, Università di Catania, Viale A. Doria, 6 95125 Catania, Italy

E-mail: [cg.fortuna@unict.it](mailto:cg.fortuna@unict.it)

Dedicated to Professor Nicolò Vivona in the occasion of his 70<sup>th</sup> anniversary

---

### Abstract

The synthesis and spectroscopic characterization of *trans* 1-(indol-2-yl)-2-(1-methylpyridinium and 1-methylquinolinium-2-yl) ethylenes is reported. *In vitro* antitumour activity tests show that quinolinium derivatives are more active towards MCF7 (breast), LNCap (prostate) and U87 (human glioblastoma) carcinoma cells than pyridinium ones.

**Keywords:** Heterocycles, organic synthesis, cytotoxicity, antitumour activity

---

### Introduction

We have recently reported the design of new *trans* 2-(furan-2-yl)vinyl heteroaromatic iodides,<sup>1</sup> with pyridinium, imidazolium and quinolinium as ethylene-linked heteroaromatic cations and halo substituted benzenes in the 5 position of the furan ring, with the aim to optimize the antitumour activities exhibited by imidazolium salts previously reported.<sup>2</sup> In fact, previous work on the design, the synthesis and the antitumour activity of new *trans* 1-heteroaryl-2-(1,3-dimethylimidazolium-2-yl) ethylenes<sup>2-5</sup> confirmed the hypothesis that the presence of three aromatic moieties and of halogen atoms are the main structural features necessary to obtain satisfactory antiproliferative activities. On the basis of these results, we decided to introduce a new benzofused heteroaromatic ring such as indole in these compounds and to link pyridinium and quinolinium cations in the 2 position of the ethylene moiety in order to compare the activities of analogous derivatives possessing 3 and 4 aromatic rings. Here we report the synthesis and the biological evaluation of new *trans* 1-indolyl-2-(1-methylheteroar-2-yl) ethylenes against three type of tumour cells.




**Table 1.** Absorption maxima for 1-indolyl-2-(1-methylheteroar-2-yl) ethylenes **1-10** in different solvents

Compounds \ Solvents	CHCl <sub>3</sub>	EtOH	MeOH	H <sub>2</sub> O	$\Delta\lambda_{\max}$ (nm) (CHCl <sub>3</sub> -H <sub>2</sub> O)	$\Delta\lambda_{\max}$ (nm) (EtOH-H <sub>2</sub> O)
<b>1</b>	-	400	380.35	378.34		21.66
<b>2</b>	-	430.73	429.72	408.56		22.17
<b>3</b>	-	479.60	419.14	414.61		64.99
<b>4</b>	443.83	431.74	430.73	417.63	26.2	
<b>5</b>	-	423.68	419.65	398.48		25.2
<b>6</b>	-	448.87	439.80	472.04		23.17
<b>7</b>	-	480.10	473.05	449.87		30.23
<b>8</b>	509.29	470.03	463.98	440.81	68.48	
<b>9</b>	505.29	487.15	483.12	467.00	38	
<b>10</b>	473.05	464.99	464.99	438.79	34.26	

However, the major purpose of the present work is to test the *in vitro* antitumour activity of the title water soluble *trans* 1-indolyl-2-(1-methylheteroar-2-yl)ethylenes and to relate the results with those of the previous studies published from our group.

The *in vitro* antitumour activity of the water soluble compounds synthesized in the present work was then tested against three tumour cell lines, breast carcinoma (MCF7), prostate carcinoma (LNCap) and human glioblastoma (U87). The *in vitro* activities, expressed as log GI<sub>50</sub> values (see Experimental Section), are recorded in Table 2, together with that of 2,6-di-[2-(furan-2-yl)vinyl]pyridinium iodide (PF<sub>2</sub>)<sup>6</sup>, the most active compounds in previous *in vitro* tests, also reported for comparisons. It is worth mentioning that, in order to obtain comparable biological tests, log GI<sub>50</sub> in Table 2 were all measured in the same experiment. The percent of growth and the inhibition exerted by different doses (0.01-100  $\mu$ M) are recorded in Figure 1. In addition to the antiproliferative effects (log GI<sub>50</sub>), two derivatives exhibit a significant cytotoxic activity, expressed as log LC<sub>50</sub> values and reported in Table 3.



**Figure 1.** Dose – response curves of the antiproliferative activities of synthesised compounds and PF2 on U87, LNCap and MCF7 cell lines.

**Table 2.** *In vitro* antitumor activities, expressed as log GI<sub>50</sub>, for U87, LNCap and MCF7 cell lines

Cmpds/ Cell line	1	2	3	4	5	6	7	8	9	10	PF <sub>2</sub>
U87	-4.20	>-4.00	-4.50	-4.37	-4.45	-5.40	-5.14	-5.42	-5.48	-4.47	-
LNCap	-4.00	>-4.00	-4.25	-4.50	-	-5.80	-5.80	-5.72	-6.48	-	-4.50
MCF-7	>-4.00	-5.00	-5.40	-5.00	-4.70	-5.60	-5.76	-	-6.38	-5.00	-4.70

**Table 3.** *In vitro* cytotoxicity, expressed as log LC<sub>50</sub>, for U87, LNCap and MCF7 cell lines

Cmpds/Cell line	8	9
U87	-4.00	-4.26
LNCap	-5.10	-

Compounds **6** and **7** in Table 2 exhibit activity values slightly better than that of PF<sub>2</sub>, while compound **9** presents the highest value recorded in Table 2, towards all three cell lines.

## Conclusions

New *trans* 1-indolyl-2-(1-methylquinolinium-2-yl) ethylene iodides tested in the present study are more active than 1,2 diheteroaryl ethylenes previously reported<sup>1,2,6,7</sup> suggesting that the presence of four aromatic moieties increase the antitumour activities. Moreover, the significant solvatochromic shifts exhibited by these new push-pull derivatives indicate them as promising candidates for further investigations aimed at non linear optics applications.

## Experimental Section

**General Procedures.** Heteroaromatic carboxaldehydes, Aldrich commercial products, were used without further purification. UV-Vis difference spectra were recorded on a Perkin Elmer Lambda 2S spectrometer. <sup>1</sup>H NMR spectra were recorded on a Varian Unity Inova spectrometer operating at 500 MHz, at 25°C in (CD<sub>3</sub>)<sub>2</sub>SO using TMS as internal standards. The spectral width was set to 5,000 Hz, with an excitation pulse of 60 degrees, an acquisition time of 3.5 s and a digital resolution after zero-filling of 0.15 Hz/pt. Fast Atom Bombardment (FAB) mass spectra were recorded on a double focusing Kratos MS 500 mass spectrometer equipped with the standard FAB source. Mass spectra ESI were recorded on a LCQ Deca Finnigan system with a flow of 5 µl/min. Compounds 1-10, all iodide salts, were obtained by refluxing in ethanol equimolar amounts of 1,2- dimethylpicolinium iodide or 1,2- dimethyl quinolinium iodide and

the appropriate indole aldehyde in the presence of few drops of base. The resulting precipitate was recrystallized from ethanol.

Details on the synthetic conditions and products characterization are reported below:

**1-(Indol-5-yl)-2-(1-methylpyridium-2-yl) ethylene iodide (1).** 20% NaOH, EtOH, 3hrs, reflux. Yields: 17%; (green prisms from ethanol); mp 244-245°C;

<sup>1</sup>H NMR, (DMSO-d<sub>6</sub>), δ= 11.41 NH (1H, s); 8.81H<sub>6</sub> (1H, d, J = 6 Hz); 8.51 H<sub>3</sub> (1H, d, J = 8 Hz); 8.41 H<sub>4</sub> (1H, t, J= 8.5 Hz); 8.05 H<sub>4'</sub>, Ha (2H, d, J = 16 Hz); 7.80 H<sub>5</sub> (1H, t, J= 7 Hz); 7.67 H<sub>6'</sub> (1H, d, J = 8.5Hz); 7.51 H<sub>b</sub> (1H, d, J = 15Hz); 7.49 H<sub>7'</sub> (1H, d, J = 8Hz); 7.45 H<sub>3'</sub> (1H, d, J = 7Hz); 6.54 H<sub>2'</sub> (1H, s); 4.35 H<sub>1</sub> (3H, s). MS : positive ESI (M<sup>+</sup> 235.3)

**1-(Indol-3-yl)-2-(1-methylpyridium-2-yl) ethylene iodide (2).** 20% NaOH, EtOH, 5hrs, reflux. Yields: 100%; (green prisms from ethanol); mp 265-266°C;

<sup>1</sup>H NMR, (DMSO-d<sub>6</sub>), δ= 8.73 H<sub>6</sub> (1H, d, J = 6Hz); 8.48 H<sub>3</sub> (1H, d, J = 8Hz); 8.34 H<sub>4</sub> (1H, t, J= 8 Hz), 8.24 Ha (1H, d, J = 15.5 Hz); 8.11 H<sub>2'</sub>, H<sub>7'</sub> (2H, t, J = 5.75 Hz); 7.67 H<sub>5</sub> (1H, t, J = 6.75 Hz); 7.52 H<sub>4'</sub> (1H, d, J = 7 Hz); 7.26 H<sub>5'</sub>, H<sub>6'</sub>, H<sub>b</sub> (3H, m, J = 16 Hz), 4.32 H<sub>1</sub> (3H, s); 11,41 NH (1H,s). MS: positive ESI (M<sup>+</sup> 235.3)

**1-(5-Br-indol-3-yl)-2-(1-methylpyridium-2-yl) ethylene iodide (3).** 20% NaOH, EtOH, 4hrs, reflux. Yields: 11%; (green needles from ethanol); mp 250-251°C;

<sup>1</sup>H NMR, (DMSO-d<sub>6</sub>), δ=12.16 NH (1H, s); 8.75 H<sub>6</sub> (1H, d, J = 6.5 Hz); 8.52 H<sub>3</sub> (1H, d, J = 8.5 Hz); 8.37 H<sub>4</sub> (1H, t); 8.28 Ha, H<sub>4'</sub> (2H, t, J = 16Hz); 7.72 H<sub>5</sub> (1H, t, J = 6.5Hz); 7.48 H<sub>6'</sub> (1H, d, J = 8Hz); 7.37 H<sub>2'</sub>, H<sub>7'</sub> (2H, m, J = 9 Hz), 7.27 H<sub>b</sub> (1H, d, J = 15 Hz), 4.32 H<sub>1</sub> (3H, s). MS : positive ESI (M<sup>+</sup> 313.2)

**1-(1-Methyl-indol-3-yl)-2-(1-methylpyridium-2-yl) ethylene iodide (4).** 20% NaOH, EtOH, 2hrs, reflux. Yields: 6%; (orange needles from ethanol); mp 276-277°C;

<sup>1</sup>H NMR, (DMSO-d<sub>6</sub>), δ=8.74 H<sub>6</sub> (1H, d, J = 6 Hz); 8.51 H<sub>3</sub> (1H, d, J = 8.5Hz); 8.34 H<sub>4</sub> (1H, t, J = 8.25 Hz); 8.24 Ha (1H, d, J = 16Hz), 8.11 H<sub>2'</sub>, H<sub>7'</sub> (2H, m); 7.68 H<sub>5</sub> (1H, t, J = 6.75 Hz); 7.59 H<sub>4'</sub> (1H, d, J = 8.5 Hz); 7.31 H<sub>5'</sub> H<sub>6'</sub> (2H, m); 7.22 H<sub>b</sub> (1H, d, J = 16Hz); 3.32 H<sub>1</sub> (3H, s); 3.31 H<sub>1'</sub> (3H, s). MS: positive ESI (M<sup>+</sup> 249.3)

**1-(Indol-4-yl)-2-(1-methylpyridium-2-yl) ethylene iodide (5).** Piperidine, EtOH, 30 minutes, reflux. Yields: 81%; (Yellow needles from ethanol); mp 243-244°C; <sup>1</sup>H NMR, (DMSO-d<sub>6</sub>), δ= 11.56 NH (1H, s); 8.88 H<sub>3</sub> (1H, d, J = 5.5Hz); 8.68 H<sub>6</sub> (1H, d, J = 8Hz); 8.48 H<sub>5</sub> (1H, t, J = 8 Hz), 8.27 Ha (1H, d, J = 16 Hz); 7.88 H<sub>4</sub> (1H, t, J = 6.75 Hz); 7.62 H<sub>6'</sub> (1H, t, J = 5.75 Hz), 7.57 H<sub>5'</sub> - H<sub>7'</sub> (2H, m); 7.23 H<sub>b</sub> - H<sub>3'</sub> (2H, t, J = 15.5 Hz), 7.02 H<sub>2'</sub> (1H, d); 3.32 H<sub>1</sub> (3H, s).. MS: positive ESI (M<sup>+</sup> 249.3)

**1-(Indol-5-yl)-2-(1-methylquinolinium-2-yl) ethylene iodide (6).** Pyperidine, EtOH, 4 hrs, reflux. Yields: 100%; (Red needles from ethanol); mp 243-245°C; <sup>1</sup>H NMR, (DMSO-d<sub>6</sub>), δ= 8.96 H<sub>4</sub> (1H, d, J = 9 Hz); 8.59 H<sub>3</sub> (1H, d, J = 9.5 Hz); 8.51 H<sub>8</sub> (1H, d, J = 9 Hz); 8.40 Ha (1H, d, J = 15.5 Hz); 8.31 H<sub>5</sub> (1H, d, J = 8Hz); 8.21 H<sub>4'</sub> (1H, s); 8.14 H<sub>6</sub> (1H, d, J = 8 Hz); 7.91 H<sub>7</sub> (1H, t, J = 7.25 Hz); 7.82 H<sub>b</sub> (1H, d, J = 16 Hz); 7.81 H<sub>6'</sub> (1H, d, J = 7.5 Hz); 7.54 H<sub>7'</sub> (1H, d, J

= 8.5 Hz) ; 7.47 H3' (1H, d, J = 8.5 Hz); 6.59 H2' (1H, s) ; 11.44 NH (1H, s) ; 4.54 H1 (3H, s). MS: positive ESI ( $M^+$  285.3)

**1-(Indol-3-yl)-2-(1-methylquinolinium-2-yl) ethylene iodide (7).** Piperidine, EtOH, 6 hrs, reflux. Yields: 50%; (green needles from ethanol); mp 253-255°C;  $^1\text{H NMR}$  , (DMSO- $d_6$ ),  $\delta$ =12.34 NH (1H, s); 8.80 H4 (1H, d, J = 9.5 Hz); 8.60 Ha (1H, d, J = 15.5 Hz), 8.56 H3 (1H, d, J = 9.5 Hz); 8.42 H8 (1H, d, J = 8.5 Hz); 8.26 H5 (1H, t, J = 8 Hz); 8.19 H5' (1H, t, J = 4.25 Hz); 8.1 H6 (1H, t, J = 7.75 Hz); 7.83 H7 (1H, t, J = 7.5 Hz); 7.56 Hb, H7' (2H, t, J = 16 Hz); 7.30 H5', H6' (2H, t, J = 4.25 Hz); 4.46 H4' (1H, d, J = 4.25 Hz); 4.40 H1 (3H, s). MS: positive ESI ( $M^+$  285.4)

**1-(5-Br-indol-3-yl)-2-(1-methylquinolinium-2-yl) ethylene iodide (8).** 20% NaOH, EtOH, 24 hrs, reflux. Yields: 65%; (orange needles from ethanol); mp 207-208°C;  $^1\text{H NMR}$  , (DMSO- $d_6$ ),  $\delta$ = 8.42 NH (1H, s) ; 8.86 H4 (1H, d, J = 9 Hz); 8.66 Ha (1H, d, J = 16 Hz), 8.63 H2' (1H, d, J = 8 Hz); 8.51 H4' (1H, s) 8.46 H5 H8 (2H, m); 8.26 H6' (1H, d, J = 7.5 Hz); 8.10 H6 (1H, t, J = 8 Hz); 7.86 H 7 (1H, t, J = 7.5 Hz); 7.63 H b (1H, d, J = 15 Hz); 7.51 H3 (1H, d, J = 9 Hz); 7.41 H7' (1H, d, J = 8.5 Hz); 4.38 H1 (3H, s) MS: positive ESI ( $M^+$  363.3,  $M^+$  365.2)

**1-(1-Methyl-indol-3-yl)-2-(1-methylquinolinium-2-yl) ethylene iodide (9).** Piperidine, EtOH, 1 hrs, reflux. Yields: 27%; (violet needles from ethanol); mp 188-190°C;  $^1\text{H NMR}$  , (DMSO- $d_6$ ),  $\delta$ =8.79 H4 (1H, d, J = 9.5 Hz); 8.57 Ha-H3 (2H, d, J = 16 Hz); 8.40 H8 (1H, d, J = 9 Hz); 8.33 H2' (1H, s); 8.22 H5 – H5' (1H, t, J = 7.75 Hz); 8.07 H6 (1H, t, J = 8 Hz); 7.82 H7 (1H, t, J = 7.5 Hz); 7.62 H7' (1H, d, J = 7.5 Hz); 7.52 Hb (1H, d, J = 15.5 Hz); 7.36 H6' (2H, t, J = 7.25 Hz); 4.62 H1 (3H, s) 4.61 H1' (3H, s). MS: positive ESI ( $M^+$  299.3)

**1-(Indol-4-yl)-2-(1-methylquinolinium-2-yl) ethylene iodide (10).** Piperidine, EtOH, 5 hrs, reflux. Yields: 82%; (red needles from ethanol); mp 221-222°C;  $^1\text{H NMR}$  , (DMSO- $d_6$ ),  $\delta$ = 9.04 NH (1H, d, J = 8.5 Hz); 8.76 H3 (1H, d, J = 9 Hz), 8.57 H8- Ha (2H, m); 8.34 H5 (1H, d, J = 8 Hz); 8.18 H6 (1H, t, J = 7.75 Hz); 7.95 H4 – H7 (2H, m); 7.81 H5' (1H, d, J = 7.5 Hz), 7.62 H7' – H3' (2H, m); 7.27 H6'-Hb (2H, dd, J = 15.5 Hz) ; 7.12 H2' (1H, s) 4.58 H1 (3H, s). MS: positive ESI ( $M^+$  285.4).

### Biological essays

**Human cell lines (LNCap, MCF7, U87).** Human prostate adenocarcinoma cells (LNCap) and human glioblastoma cells (U87) were grown in RPMI 1640. Human mammary adenocarcinoma (MCF7) were grown in Dulbecco's MEM (DMEM), 1.0 g/l D-glucose. Each medium was supplemented with 10% (vol/vol) heat-inactivated fetal bovine serum, 2mM L-Alanyl-L-Glutamine, penicillin-streptomycin (50 units-50  $\mu\text{g}$  for ml) and incubated at 37 °C in humidified atmosphere of 5%  $\text{CO}_2$ , 95% air. The culture medium was changed twice a week.

**Treatment with antitumour agents and MTT colorimetric assay.** Each human cancer cell line ( $5 \times 10^3$  cells/ $0.33\text{cm}^2$ ) were plated in 96 well plates "Nunclon TM Microwell TM" (Nunc) and were incubated at 37 °C. After 24 h, cells were treated with the compounds (final concentration 0.01-100  $\mu\text{M}$ ). Untreated cells were used as controls. Microplates were incubated at 37 °C in humidified atmosphere of 5%  $\text{CO}_2$ , 95% air for 3 days and then cytotoxicity was measured with

colorimetric assay based on the use of tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide).<sup>8</sup> The results were read on a multiwell scanning spectrophotometer (Multiscan reader), using a wavelength of 570 nm. Each value was the average of 8 wells (standard deviations were less than 20%). The GI<sub>50</sub> value was calculated according to NCI: thus, GI<sub>50</sub> is the concentration of test compound where  $100 \times (T - T_0)/(C - T_0) = 50$  (T is the optical density of the test well after a 48-h period of exposure to test drug; T<sub>0</sub> is the optical density at time zero; C is the control optical density).

## Acknowledgements

Financial support of the University of Catania is gratefully acknowledged.

## References

1. Fortuna, C. G.; Barresi, V.; Berellini, G.; Musumarra, G. *Bioorg. Med. Chem.* **2008**, *16*, 4150.
2. Ballistreri, F. P.; Barresi, V.; Benedetti, P.; Caltabiano, G.; Fortuna, C. G.; Longo, M. L.; Musumarra, G. *Bioorg. Med. Chem.* **2004**, *12*, 1689.
3. Goodford, P. *J. Med. Chem.* **1985**, *28*, 849.
4. Cramer III, R. D.; Patterson, D. E.; Bunce J. *J. Am. Chem. Soc.* **1988**, *110*, 5959.
5. Pastor, M.; Cruciani, G.; McLay, I.; Pickett, S.; Clementi, S. *J. Med. Chem.* **2000**, *43*, 3233.
6. Barresi, V.; Condorelli, D. F.; Fortuna, C. G.; Musumarra G.; Scirè, S. *Bioorg. Med. Chem.* **2002**, *10*, 2899.
7. Ballistreri, F. P.; Barresi, V.; Consiglio, G.; Fortuna, C. G.; Longo, M. L.; Musumarra, G. *Arkivoc* **2003**, *part(i)*, 105.
8. Mosmann, T. *J. Immunol. Meth.* **1983**, *65*, 55.